A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

Systemic lupus erythematosus-disease activity score remission and low disease activity were similarly associated with patient-reported outcomes compared with definition of remission in systemic lupus erythematosus remission and lupus low disease activity state

Rheumatology (Oxford)

Nakanishi E, Matsushita M, Minowa K, Tada K, Kawamoto T, Kusaoi M, Amano H, Kon T, Morimoto S, Ikeda K, Suzuki S, Nozawa K, Yang KS, Matsudaira R, Katagiri A, Tsushima H, Urasaki W, Nojiri S, Yamaji K, Tamura N

doi: 10.1093/rheumatology/keaf349

Systemic Lupus Erythematosus

LLDAS and remission attainment with anifrolumab treatment in patients with systemic lupus erythematosus: results from the TULIP and long-term extension randomised controlled trials

Ann Rheum Dis

Morand EF, van Vollenhoven R, Furie RA, Kalunian KC, Manzi S, Abreu G, Tummala R, Duncan EA, Al-Mossawi H, Lindholm C

doi: 10.1016/j.ard.2025.01.016

Systemic Lupus Erythematosus

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: A Multicenter, Open-Label Trial

Arthritis Care Res (Hoboken)

Brunner HI, Antón J, Calvo-Penadés I, Dimelow R, Horneff G, Kamphuis S, Marino R, van Maurik A, Minden K, Mori M, Ocran-Appiah J, Wilkinson C, Yamasaki Y, Assudani D, Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) network investigators

doi: 10.1002/acr.25700

Immune Response

A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy

N Engl J Med

Lafayette R, Barbour SJ, Brenner RM, Campbell KN, Doan T, Eren N, Floege J, Jha V, Kim BS, Liew A, Maes B, Pal A, Pecoits-Filho R, Phoon RKS, Rizk DV, Suzuki H, Tesař V, Trimarchi H, Wei X, Zhang H, Barratt J, ORIGIN Phase 3 Trial Investigators

doi: 10.1056/NEJMoa2510198

Systemic Lupus ErythematosusSystemic Sclerosis

Menopausal hormone therapy and the risk of systemic lupus erythematosus and systemic sclerosis: a population-based nested case-control study

Rheumatology (Oxford)

Patasova K, Dehara M, Mantel Ä, Bixo M, Arkema E, Holmqvist M

doi: 10.1093/rheumatology/keaf004

Psoriasis

Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical Trial

JAMA Dermatol

Gooderham MJ, Alonso-Llamazares J, Bagel J, Bhatia N, Bukhalo M, DuBois J, Ferris LK, Green L, Kircik LH, Lockshin B, Loo WJ, Papp KA, Soung J, Seal MS, Snyder S, Kato S, Krupa D, Burnett P, Berk DR, Chu DH

doi: 10.1001/jamadermatol.2025.1136

Atopic Dermatitis

Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis

J Am Acad Dermatol

Bissonnette R, Gold LS, Kircik L, Simpson EL, Eichenfield LF, Browning J, Hebert AA, Alexis AF, Soong W, Piscitelli SC, Tallman AM, Rubenstein DS, Brown PM, Silverberg JI

doi: 10.1016/j.jaad.2025.05.1391

Systemic Lupus Erythematosus

Polypharmacy in Adults with Systemic Lupus Erythematosus

Arthritis Care Res (Hoboken)

Yang J, Growdon ME, Fitzpatrick J, Dunlop-Thomas C, Hoge C, Covinsky KE, Bowling CB, Lim SS, Yazdany J, Plantinga LC

doi: 10.1002/acr.25686

Further Publications Immunology

Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial

N Engl J Med

Perkovic V, Trimarchi H, Tesar V, Lafayette R, Wong MG, Barratt J, Suzuki Y, Liew A, Zhang H, Carroll K, Jha V, Quevedo A, Han SH, Praga M, Chacko B, Sahay M, Cheung CK, Kooienga L, Walsh M, Xia J, Fajardo C, Shah L, Hafkin J, Rizk DV, VISIONARY Trial Investigators Group

doi: 10.1056/NEJMoa2512133

Related content

Systemic lupus erythematosus-disease activity score remission and low disease activity were similarly associated with patient-reported outcomes compared with definition of remission in systemic lupus erythematosus remission and lupus low disease activity state

LLDAS and remission attainment with anifrolumab treatment in patients with systemic lupus erythematosus: results from the TULIP and long-term extension randomised controlled trials

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: A Multicenter, Open-Label Trial

A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy

Menopausal hormone therapy and the risk of systemic lupus erythematosus and systemic sclerosis: a population-based nested case-control study

Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical Trial

Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis

Polypharmacy in Adults with Systemic Lupus Erythematosus

Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial